186519-89-1

Basic information

• Product Name: 4-CHLORO-7-(PHENYLSULFONYL)-7H-PYRROLO[2,3-D]PYRIMIDINE
• Synonyms: 4-CHLORO-7-(PHENYLSULFONYL)-7H-PYRROLO[2,3-D]PYRIMIDINE;7-(benzenesulfonyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine;7-(benzenesulfonyl)-4-chloropyrrolo[2,3-d]pyrimidine
• CAS NO: 186519-89-1
• Molecular Formula: C₁₂H₈ClN₃O₂S
• Molecular Weight: 293.73
• Mol File: 186519-89-1.mol

Chemical Properties

• Boiling Point: 502.4±53.0 °C(Predicted)
• Appearance: /
• Density: 1.54±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.81±0.30(Predicted)
• CAS DataBase Reference: 4-CHLORO-7-(PHENYLSULFONYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-7-(PHENYLSULFONYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(186519-89-1)
• EPA Substance Registry System: 4-CHLORO-7-(PHENYLSULFONYL)-7H-PYRROLO[2,3-D]PYRIMIDINE(186519-89-1)

Safety Data

• Hazardous Substances Data: 186519-89-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-Chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is utilized as a key intermediate in the synthesis of various pharmaceutical agents. Its unique structure and properties make it a valuable component in the creation of new drugs with potential applications in treating a range of diseases.
Used in Cancer Treatment:
In the field of oncology, 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is employed as a potential anticancer agent. Its biological activity is being studied for its capacity to target and inhibit the growth of cancer cells, offering a new avenue for therapeutic intervention in cancer treatment.
Used in Inflammation Management:
4-Chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is also considered for use in managing inflammatory conditions. Its potential to modulate inflammatory responses is under investigation, with the aim of developing it into a treatment for various inflammatory diseases.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine serves as a structural template for the design and optimization of new pharmaceutical compounds. Its unique features facilitate the development of molecules with enhanced efficacy and selectivity for specific biological targets.
Used in Drug Discovery:
4-Chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is utilized in high-throughput screening processes for drug discovery. Its presence in compound libraries allows researchers to identify potential lead candidates for further development into effective therapeutic agents.
Used in Chemical Synthesis:
In the chemical synthesis industry, 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a building block for the creation of complex organic molecules. Its versatile chemical properties enable it to be a component in the synthesis of a variety of organic compounds with diverse applications.

Upstream product

• 3680-71-5 7-deazahypoxanthine 
• 3680-71-5 Allopurinol 
• 98-09-9 benzenesulfonyl chloride 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 212268-44-5 4-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine 
• 876343-10-1 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 1643962-37-1 (R)-6-iodo-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1637569-25-5 C₁₃H₁₀FIN₄ 
• 1643962-38-2 (S)-2-((6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol 
• 1637437-41-2 C₁₄H₁₂FIN₄O 
• 1637438-20-0 C₂₁H₂₀N₄O 
• 1637438-32-4 C₂₀H₁₈N₄O 
• 1637438-64-2 C₂₀H₁₈N₄O 
• 1637569-24-4 C₂₁H₂₀N₄O 
• 497841-30-2 {3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanol 
• 497841-27-7 {4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanol 
• 1637437-71-8 (R)-3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzaldehyde 
• 1637437-39-8 (R)-(3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanol 

Relevant articles and documents

Optochemical control of transcription by the use of 7-deaza-adenosine-based diarylethenes

Out of nine different 7-deaza-adenosine diarylethenes, we identified a high-performance photoswitch, suitable for the synthesis of photochromic DNA. By using solid phase synthesis, a photoresponsive T7 promotor was generated which allowed reversibly modulating the rate of enzymatic RNA synthesisin vitro.

(1R, 4R, 7R) -7 - amino -2 - azabicyclo [2, 2, 1] heptane derivatives and preparation method thereof

The invention belongs to the field of medicines, and discloses (1R, 4R, 7R) -7 - amino -2 - azabicyclo [2, 2, 1] heptane derivatives and a preparation method thereof, which comprises: (S1) compound I - 1 and I - 2 carrying out nucleophilic aromatic substi

IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions compris

The condensed heterocyclic compound such as Bruton kinase inhibitors (by machine translation)

The invention relates to a fused heterocycle derivative and an application, which has a structure shown in a formula 1). The compound with the structure shown in the formula 1) has good inhibition effect to Bruton kinases activity, and median inhibitory concentration is lower than 10mol.L generally.

NOVEL PYRROLOPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases in which the

ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter

Preparation method of baricitinib

The invention discloses a preparation method of baricitinib. The method comprises the following steps: performing a substitution reaction on 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (II) serving as a raw material and benzene sulfonyl chloride in the presence of an alkali to obtain an intermediate III; then, performing a Suzuki coupling reaction on the intermediate III and 4-pyrazole-4-boronic acid pinacol ester in the presence of a palladium catalytic system and an alkali to obtain an intermediate V; then performing a Michael addition reaction on the intermediate V and 3-(cyanomethylene)azetidine-1-tert-butyl formate in the presence of a catalyst to obtain an intermediate VII; then removing Boc protection from the intermediate VII under the action of hydrochloric acid to obtain an intermediate VIII; then performing a sulfoamidate reaction on the intermediate VIII and ethyl sulfonyl chloride in an organic solvent in the presence of an alkali to obtain an intermediate IX; lastly, removing benzenesulfonyl protection from the intermediate IX under the action of tetramethylammonium fluoride or tetrabutylammonium fluoride or a trihydrate of the tetramethylammonium fluoride or the tetrabutylammonium fluoride to obtain baricitinib (I). Compared with the prior art, the method has the advantages of adoption of readily-available raw materials, low cost, high product yield and easiness for industrial production.

The role of alkyl substituents in deazaadenine-based diarylethene photoswitches

Diarylethenes are an important class of reversible photoswitches and often claimed to require two alkyl substituents at the carbon atoms between which the bond is formed or broken in the electrocyclic rearrangement. Here we probe this claim by the synthesis and characterization of four pairs of deazaadenine-based diarylethene photoswitches with either one or two methyl groups at these positions. Depending on the substitution pattern, diarylethenes with one alkyl group can exhibit significant photochromism, but they generally show poor stability towards extended UV irradiation, low thermal stability, and decreased fatigue resistance. The results obtained provide an important direction for the design of new efficient DNA photoswitches for the application in bionanotechnology and synthetic biology.